Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database - Scorecard - MDSpire
Advertisement
Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database
Clinical Scorecard: Linking ciltacabtagene autoleucel to immune effector cell-associated enterocolitis: findings from a comprehensive national database
Direct infiltration of CAR T-cells into gut mucosa causing mucosal injury with intraepithelial lymphocytosis, villous blunting, and GVHD-like pathology; multifactorial process involving persistent CAR T-cell activation, cytokine-mediated inflammation, and possible off-tumour, on-target effects against BCMA-expressing gut cells
Target Population
Patients with multiple myeloma treated with ciltacabtagene autoleucel (anti-BCMA CAR T-cell therapy)
Care Setting
Specialized oncology and hematology centers administering CAR T-cell therapies
Key Highlights
IEC-EC is a rare but serious delayed immune-mediated toxicity occurring weeks to months after ciltacabtagene autoleucel therapy.
FAERS database analysis identified 31 cases of IEC-EC exclusively linked to ciltacabtagene autoleucel with a strong disproportionality signal (ROR 83.65).
Differences in CAR T-cell construct binding avidity may explain the higher IEC-EC reports with ciltacabtagene autoleucel compared to idecabtagene vicleucel.
Guideline-Based Recommendations
Diagnosis
Consider IEC-EC in patients presenting with acute severe non-bloody diarrhea and gut inflammation weeks to months post-CAR T-cell therapy after excluding infectious causes.
Use clinical history, endoscopic evaluation, and histopathology demonstrating mucosal injury with GVHD-like features for diagnosis.
Management
Initiate systemic corticosteroids as first-line therapy for IEC-EC.
Monitor response to corticosteroids and consider additional immunosuppressive therapies if refractory.
Monitoring & Follow-up
Close clinical monitoring for gastrointestinal symptoms in patients receiving ciltacabtagene autoleucel.
Monitor CAR T-cell expansion kinetics and inflammatory cytokine levels as potential indicators of immune-mediated toxicities.
Risks
Risk factors for IEC-EC remain unclear; no validated biomarkers currently exist to predict susceptibility.
Potential off-tumour, on-target effects due to BCMA expression in gut mucosa may contribute but lack direct evidence.
Patient & Prescribing Data
Multiple myeloma patients treated with FDA-approved CAR T-cell therapies, specifically ciltacabtagene autoleucel
IEC-EC has been reported exclusively with ciltacabtagene autoleucel among CAR T-cell products in FAERS data, suggesting a product-specific risk possibly related to construct binding avidity and expansion kinetics.
Clinical Best Practices
Maintain high suspicion for IEC-EC in patients with delayed gastrointestinal symptoms post ciltacabtagene autoleucel.
Exclude infectious etiologies before diagnosing IEC-EC.
Employ systemic corticosteroids promptly upon diagnosis to mitigate inflammation.
Recognize limitations of pharmacovigilance databases; use data as hypothesis-generating rather than definitive incidence or causality evidence.
Encourage ongoing pharmacovigilance and research to better characterize IEC-EC risk factors and management.
